FDA Advisory Panel Votes Against New Use of AbbVie's Humira

Published: Jul 25, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

An advisory panel to the U.S. Food and Drug Administration voted against approving AbbVie Inc's rheumatoid arthritis drug Humira for treating an inflammatory disease of the spine. The panel of independent advisors called for additional trials to prove the efficacy of the drug in treating early-stages of spondyloarthritis. The FDA will take the panel's 12 to 1 vote into consideration while deciding upon the final approval for this new use for the drug.

Help employers find you! Check out all the jobs and post your resume.

Back to news